Sagimet Biosciences Inc——2026年季度报告

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ Table of Contents Table of Contents PARTI- FINANCIAL INFORMATION Item1.Condensed Financial Statements Condensed Balance Sheets (unaudited)Condensed Statements of Operations and Comprehensive Loss (unaudited)Condensed Statements of Stockholders’ Equity (unaudited)Condensed Statements of Cash Flows (unaudited)Notesto Condensed Financial Statements (unaudited)Item2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem3.Quantitative and Qualitative Disclosures About Market RiskItem4.Controls and ProceduresPARTII- OTHER INFORMATION Item1.Legal ProceedingsItem1A. Risk FactorsItem2.Unregistered Sales of Equity Securities and Use of ProceedsItem3.Defaults Upon Senior SecuritiesItem4.Mine Safety DisclosuresItem5.Other InformationItem6.ExhibitsSignatures FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this Quarterly Report) contains forward-looking statements within themeaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of theSecurities Exchange Act of 1934, as amended (the Exchange Act). All statements other than statements of historicalfacts contained in this Quarterly Report, including statements regarding our future results of operations and financialposition, business strategy, drug candidates, planned preclinical studies and clinical trials, results of preclinical studies,clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,”“expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential,” or“continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this ●our financial performance; ●our ability to obtain additional cash and the sufficiency of our existing cash, cash equivalents and marketablesecurities to fund our future operating expenses and capital expenditure requirements; ●the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs foradditional financing; ●the scope, progress, results and costs of developing denifanstat, TVB-3567 or any other drug candidates orcombination therapies we may develop, and conducting preclinical studies and clinical trials; ●our ability to advance drug candidates into, and successfully complete, clinical trials within anticipatedtimelines; ●the timing and costs involved in obtaining and maintaining regulatory approval of denifanstat, TVB-3567 orany other drug candidates or combination therapies we may develop, and the timing or likelihood of ●current and future agreements with third parties in connection with the development and commercialization of ●our estimate of the number of patients in the United States who suffer from the diseases we target and the ●our relationship with Ascletis BioScience Co. Ltd. (Ascletis), and its affiliate Gannex Pharma Co., Ltd.(Gannex), and the success of their development and registration efforts for denifanstat in China; ●the ability of our clinical trials to demonstrate the safety and efficacy of denifanstat, TVB-3567 and any otherdrug candidates or combination therapies we may develop; ●our plans relating to commercializing denifanstat, TVB-3567 and any other drug candidates or combinationtherapies we may develop, if approved, including the geographic areas of focus and our ability to build a ●the success of competing therapies that are or may become available; ●our plans relating to the further development and manufacturing of denifanstat, TVB-3567 and any other drugcandidates or combination therapies we may develop, including additional indications that we may pursue for ●our ability to obtain sufficient non-dilutive funding or enter into a strategic collaboration to initiate futureclinical trials for our combination of denifanstat and resmetirom in metabolic dysfunction-associated ●existing regulations and regulatory developments in the United States and other jurisdictions; ●our potential and ability to successfully manufacture and supply denifanstat, TVB-3567 and any other drugcandidates or combination therapies we may develop for clinical trials and for commercial use, if approved; ●the rate and degree of market